Umedeor
- Company typePrivate
- Founded2021
- HeadquartersLondon, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
Umedeor firmographics
Firmographics- Name
- Umedeor
- Legal name
- uMed Technologies Inc.
- Website
- https://umed.io
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Where Umedeor is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Umedeor business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical Research Services: uMed provides modular study services including recruitment, data collection, sampling, and study management for pharmaceutical sponsors, CROs, and research institutions. Revenue is generated through service contracts for clinical trials and observational studies.
- Cohort Access Subscriptions: ACCESS Cohorts provide reusable, scalable research resources. Sponsors and researchers pay for access to prospectively recruited patient populations linked to EHR data for evidence generation across drug development lifecycle stages.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom enterprise pricing based on study requirements |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Umedeor product offering
Product offeringCore offering
Umedeor (uMed) operates an AI-driven clinical research platform that combines electronic health record (EHR) integration with pre-consented patient cohorts to enable decentralized clinical trials and real-world evidence generation for pharmaceutical sponsors, contract research organizations (CROs), and academic research institutions. The platform supports the full drug development lifecycle through modular study services including patient recruitment, decentralized data collection, and longitudinal cohort studies across disease-specific registries for cardiometabolic disease, Parkinson's disease, and interstitial lung disease.
Product overview
uMed is a clinical research technology company offering a platform-plus-modules architecture for evidence generation in clinical trials and real-world research. The core offering is the ACCESS Cohorts platform (with SpanACCESS for longitudinal evidence and SnapACCESS for rapid qualitative insights), supported by Study Services modules (Collect for decentralized data collection and Recruit for patient recruitment). Disease-specific research platforms include ACCESSCMD (cardiometabolic), ACCESSPD (Parkinson's disease), and ACCESSILD (interstitial lung disease). The platform links consented patients with their routine care data via EHR integration and enables remote engagement for decentralized clinical research.
Differentiator
Problem solved
Functional benefit
Brands
- AccessCMD: Next-generation cardiometabolic research cohort - disease-specific registry embedded within ACCESS research-ready infrastructure for cardiometabolic disease studies.
- AccessPD
- AccessILD
- ACCESS Cohorts
- SpanACCESS
- SnapACCESS
- ACCESS Platform
Products and services
- ACCESS Cohorts Prospectively recruited, EMR-linked registries that follow real patients over time. Built to be reusable, scalable living research resources linking consented patients with their routine care data and enabling remote engagement for faster, more representative evidence generation. Designed for pharmaceutical sponsors, CROs, and research institutions needing longitudinal real-world data.
- SpanACCESS Flexible, longitudinal engine for real-world evidence generation. Enables customizable, real-world studies using pre-consented, EMR-linked patient cohorts with multi-timepoint data capture (baseline, 3, 6, 12+ months) for clinical strategy, regulatory submission, and post-market evidence.
- SnapACCESS Rapid qualitative research solution bridging patient voice and clinical reality. Delivers verified patient cohorts linked to EHR data with integrated qualitative feedback and real-time insights in under 4 weeks, combining traditional qualitative research speed with clinical validation.
- ACCESSCMD Cardiometabolic disease cohort embedded within the ACCESS research infrastructure. Identifies and invites eligible individuals receiving routine care via secure EHR integration. Links longitudinal clinical data with patient-reported outcomes and home-collected biomarker or genetic data across US and UK.
- ACCESSPD Next-generation, remote Parkinson's disease registry. Uses electronic health record data to identify and invite patients with confirmed diagnosis across US and UK. Links routine clinical data with ongoing patient-reported outcomes and genetic or biomarker data collected from home.
- ACCESSILD Next-generation interstitial lung disease registry. Uses EHR data to identify and invite patients with confirmed diagnosis across US and UK. Links routine clinical data with patient-reported outcomes and genetic or biomarker data collected from home for inclusive research and patient stratification.
- uMed Collect Decentralized, longitudinal data collection service. Supports patient-centric trials with remote bio-sampling, smart data collection (ePRO, EHR, primary and secondary care data), patient support hub, and decentralized trial services. Modular system configured per trial needs.
- uMed Recruit
Quantifiable outcome
- 6,500 patient responses collected in 5 days for GLP-1 survey
- +8 more outcomes
Companies that use Umedeor
Customer profileNamed customers22 records
Segments1 record
Ideal customer profiles2 records
Umedeor technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature8 records
Umedeor partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and supporting.
- CeracorePartnership to bring clinical research to the point of care, expanding trial recruitment to a long-underserved 65+ cohort. Cera's care delivery platform enables identification of eligible older patients for research opportunities.
- WellSkycoreStrategic partnership to expand patient access to national clinical research registries, focusing initially on cardiometabolic and Parkinson's disease cohorts in 2026 with plans to include additional therapeutic areas. WellSky provides EHR network infrastructure enabling uMed to identify eligible home care patients for remote research participation.
- Decisive ConsultingsupportingPartnership to drive data-driven market access success in cardiometabolic and Parkinson's disease research. Decisive Consulting provides market access expertise complementary to uMed's patient data capabilities.
- Global Parkinson's Genetics Program (GP2)corePartnership to address emerging research demands in Parkinson's disease through integrated genetic research capabilities. uMed provides patient cohort access and data collection supporting GP2's global genetics initiative.
- Michael J. Fox FoundationcorePartnership for Parkinson's disease research, supporting the PPMI study. Deploys physical smell test kits to patients and facilitates patient referrals to research sites. Over 1,200 kits deployed and 400 patients referred.
- Our Future HealthsupportingPartnership with UK's largest health research programme to support population health research initiatives and expand patient recruitment capabilities.
- MCI OnehealthsupportingPartnership to accelerate clinical research in Canada by expanding uMed's North American presence and leveraging MCI Onehealth's healthcare network.
- EMIS HealthcoreAccredited partner status with EMIS Health, a leading UK electronic health record provider. Partnership enables secure integration with primary care EHR systems for patient identification and data linkage.
- AstraZenecasupportingPharmaceutical partner listed among key institutions collaborating with uMed for clinical research initiatives.
- SanofisupportingPharmaceutical partner listed among key institutions collaborating with uMed for clinical research initiatives.
- ModernasupportingPharmaceutical partner listed among key institutions collaborating with uMed for clinical research initiatives.
- King's College LondonsupportingAcademic research partner listed among key institutions collaborating with uMed for clinical research initiatives.
- University of OxfordsupportingAcademic research partner listed among key institutions collaborating with uMed for clinical research initiatives.
- Queen Mary University of LondonsupportingAcademic research partner collaborating on PREDICT-PD and other Parkinson's disease research studies. Prof. Alastair Noyce serves on uMed's Advisory Board.
- FortreasupportingContract research organization partner listed among key collaborators for clinical trial support services.
Scale indicators16 records
Recent moves6 records
Expansion highlights6 records
Umedeor competitors and assessment
Company assessmentBroad incumbents
- Medidata (Dassault Systèmes): Industry-leading clinical trial technology platform offering EDC, eCOA, randomization, and trial management. Comparable as the dominant incumbent in clinical trial data infrastructure that uMed's ePRO and EHR-linked cohort capabilities must integrate with or differentiate against.
- IQVIA: World's largest CRO with comprehensive clinical research services, real-world evidence, and patient recruitment capabilities. Broad incumbent comparable to uMed's full-service study offering plus RWE platform; competes for the same enterprise sponsor relationships.
- Verily (Alphabet): Alphabet-owned health technology company with clinical research platforms including decentralized trials and real-world evidence tools. Comparable as a well-capitalized incumbent building EHR-integrated research infrastructure that overlaps with uMed's value proposition.
Direct peers
- TriNetX: Global real-world evidence and clinical trial recruitment platform built on EHR-linked patient data from health systems. Directly comparable to uMed in using EHR data to identify eligible patients, accelerate trial recruitment, and generate evidence for pharma sponsors.
- Castor: Cloud-based clinical trial data capture platform with ePRO/eCRF capabilities and decentralized trial support. Comparable as a tech-enabled clinical research platform targeting faster, more efficient study delivery for academic and commercial sponsors.
- Reify Health: Clinical trial recruitment and site performance platform (StudyTeam, Care Access). Directly comparable to uMed Recruit as an enterprise platform focused on accelerating patient identification, enrollment, and trial site coordination.
- ObvioHealth: Decentralized clinical trial platform offering remote patient data collection, ePRO, and virtual site operations. Comparable to uMed's decentralized trial capabilities (uMed Collect, ACCESS Cohorts) with overlapping technology stack.
- THREAD: Decentralized clinical trial technology platform supporting eCOA, ePRO, remote consent, and telehealth-based study visits. Directly comparable to uMed's decentralized study services and remote data collection infrastructure.
- Deep 6 AI: AI-powered patient matching platform that mines EHR data to accelerate clinical trial recruitment. Directly comparable to uMed's AI-driven patient identification and EHR-matching capabilities for clinical trial enrollment.
Emerging players
- Mendel: AI platform for clinical trial patient matching and real-world evidence generation using structured and unstructured EHR data. Comparable emerging player using AI to identify eligible patients and accelerate trial recruitment in the same category as uMed Recruit.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Umedeor social profiles
Digital presenceUmedeor compliance and trust
Trust signalCompliance6 records
Umedeor financial estimates
Financial estimateRevenue estimate
Valuation estimate
Umedeor leadership team
Management profileNumber of profiles
Profiles11 records
Umedeor subsidiaries and ownership
Company hierarchySubsidiaries3 records
Umedeor funding detail
Funding detailFunding overview
Funding rounds5 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Umedeor M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Umedeor
What does Umedeor do?
Umedeor (uMed) operates an AI-driven clinical research platform that combines electronic health record (EHR) integration with pre-consented patient cohorts to enable decentralized clinical trials and real-world evidence generation for pharmaceutical sponsors, contract research organizations (CROs), and academic research institutions. The platform supports the full drug development lifecycle through modular study services including patient recruitment, decentralized data collection, and longitudinal cohort studies across disease-specific registries for cardiometabolic disease, Parkinson's disease, and interstitial lung disease.
Is Umedeor a public or private company?
Umedeor is a private company. It is classified as venture growth investor backed and is currently operating.
When was Umedeor founded?
Umedeor was founded in 2021. It employs 51 to 100 people.
Where is Umedeor based?
Umedeor is headquartered in London, United Kingdom, in the Europe region.
How does Umedeor make money?
Two revenue lines are on record. Clinical Research Services are the primary driver. The others are cohort Access Subscriptions.
Who are Umedeor's main competitors?
Broad incumbents on record are Medidata (Dassault Systèmes), IQVIA and Verily (Alphabet). Direct peers are TriNetX, Castor, Reify Health, ObvioHealth, THREAD and Deep 6 AI. Mendel is listed as an emerging player.
Does Umedeor have an API?
No public API is recorded for Umedeor.